41 reports of this reaction
1.9% of all NELARABINE reports
#11 most reported adverse reaction
GUILLAIN BARRE SYNDROME is the #11 most commonly reported adverse reaction for NELARABINE, manufactured by Novartis Pharmaceuticals Corporation. There are 41 FDA adverse event reports linking NELARABINE to GUILLAIN BARRE SYNDROME. This represents approximately 1.9% of all 2,208 adverse event reports for this drug.
Patients taking NELARABINE who experience guillain barre syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GUILLAIN BARRE SYNDROME is a less commonly reported adverse event for NELARABINE, but still significant enough to appear in the safety profile.
In addition to guillain barre syndrome, the following adverse reactions have been reported for NELARABINE:
GUILLAIN BARRE SYNDROME has been reported as an adverse event in 41 FDA reports for NELARABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GUILLAIN BARRE SYNDROME accounts for approximately 1.9% of all adverse event reports for NELARABINE, making it a notable side effect.
If you experience guillain barre syndrome while taking NELARABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.